prtx007

PRTX007 is an orally administered prodrug of PRX034, a small molecule agonist targeting toll-like receptor 7 (TLR7). Developed by Primmune Therapeutics, PRTX007 is designed to provide controlled and well-tolerated stimulation of the innate immune system. Its mechanism involves selective activation of plasmacytoid dendritic cells (pDCs), leading to a systemic poly-interferon (Type I/III IFN) response without triggering significant production of NF-κB-driven proinflammatory cytokines such as IL-6, TNFα, or IL-1β. This approach aims to harness antiviral and antitumor immunity while minimizing inflammatory side effects. PRTX007 has demonstrated favorable safety and tolerability in Phase 1 studies with healthy volunteers, showing dose-dependent pharmacokinetics and robust activation of interferon-stimulated genes as well as CD8+ T cell and NK cell responses. It is being developed for use in combination with checkpoint inhibitors for solid tumors, for curative treatment strategies in chronic hepatitis B virus infection, and has potential applications in acute viral diseases including SARS-CoV-2[1][2][3][4][5][6][7][8].

Other names

prx034prx-034prx 034